Correction: Emerging strategies in colorectal cancer immunotherapy: enhancing efficacy and survival

There was a mistake in Table 7 as published. The phases corresponding to NCT06751966 and NCT06751914 were omitted. The corrected Table 7 appears below.

Table 7.

Clinical trials based on neoantigen vaccines for the treatment of colorectal cancer.

ClinicalTrials.Gov identifier	Combinatorial agent(s)	Phase	Primary endpoint	Status
NCT03948763	Pembrolizumab	Phase 1	DLTs	Terminated
NCT06195384		Phase 1	Safety	Recruiting
NCT06496373		Phase 1	Reaction of antigen-specific T cells	Recruiting
NCT05359354		Not Applicable	MTD,DLTs	Recruiting
NCT05916248	Pembrolizumab	Phase 1	MTD,DLTs,ORR,DCR	Recruiting
NCT05940181	Sintilimab	Interventional	MTD,DLTs,Safety	Recruiting
NCT06497010		Phase 1	RP2D	Recruiting
NCT03639714	Nivolumab;Ipilimumab	Phase 1,2	TEAEs,DLTs,ORR, RP2D	Completed
NCT06751966		Not Applicable	ORR,DCR,Safety	Recruiting
NCT06751914		Not Applicable	ORR,DCR,Safety	Recruiting
NCT04147078		Phase 1	DFS	Recruiting
NCT04117087	Nivolumab;Ipilimumab	Phase 1	Safety,Fold change in CD8 and CD4 T cells	Recruiting
NCT02600949		Phase 1	Feasibility,TEAEs	Recruiting
NCT03552718		Phase 1	Safety,RP2D	Active
NCT04041310	Pembrolizumab	Phase 1,2	DLTs,ORR,Safety, Tolerability	Active
NCT03953235	Nivolumab;Ipilimumab	Phase 1,2	TEAEs,DLTs, ORR, RP2D	Completed
NCT04912765	Nivolumab	Phase 2	PFS	Recruiting
NCT06522919	Pembrolizumab	Phase 2	ORR,PFS	Recruiting
NCT05141721	Atezolizumab;Fluoropyrimidine;Bevacizumab;Ipilimumab	Phase 2,3	ctDNA,PFS	Active

The original version of this article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.